Richard M. Hellman, MD

Site Affiliation

Oncology & Hematology Associates, P.C.
Shaw's Cove Three, Suite 201
New London, CT 06320
Tel: 860-439-1770
Fax: 860-447-2854

Education

1974 B.A.: Rutgers College, New Brunswick, New Jersey
1978 M.D.: Bowman Gray School of Medicine, Winston-Salem, North Carolina

Postdoctoral Training:

Internship and Residencies:

1978-1979: Intern in Medicine, North Carolina Baptist Hospital
1979-1981: Resident in Medicine, North Carolina Baptist Hospital

Fellowships:

1981-1982: Clinical Fellow, Hematology-Oncology Division, Beth Israel Hospital
1981-1982: Clinical Fellow in Medicine (TS), Harvard Medical School
1982-1984: Research Fellow, Hematology-Oncology Division, Beth Israel Hospital
1982-1984: Research Fellow in Medicine (TS), Harvard Medical School

Licensure and Certification:

1979: National Board of Medical Examiners
1981: American Board of Internal Medicine
1983: American Board of Internal Medicine, Subspecialty Board in Medical Oncology
1984: Connecticut License Registration
1984: American Board of Internal Medicine, Subspecialty Board in Hematology
1997: Rhode Island License Registration

Academic Appointments:

1985-1993: Assistant Professor of Medicine, University of Connecticut Medical School
1993-1995: Associate Professor of Clinical Medicine, University of Connecticut Medical School

Hospital Appointments:

1984-1985: Attending Physician in Internal Medicine, Addison Gilbert Hospital, Gloucester, Massachusetts
1985-1995: Assistant Attending Staff, Department of Medicine, Saint Francis Hospital, Hartford, Connecticut
1993-1995: Chief, Section of Hematology-Oncology, St. Francis Hospital, Hartford, Connecticut
1995-2002: Medical Director, Community Cancer Center Lawrence & Memorial Hospital, New London, Connecticut

Awards and Honors:

1974: Graduate, With High Honors, Rutgers College
1978: Duke Endowment Scholarship
1982: Diplomate, American Board of Internal Medicine
1992: Fellow, American College of Physicians
2003-2004: Voted Best Doctor
2007-2008: Voted Best Doctor

Committee Assignments:

University of Connecticut Medical School:

1985-1995: Hematology Subject Committee
1994-1995: Representative at-large, University of Connecticut School of Medicine Council

Lawrence & Memorial Hospital:

1995-2002: Medical Executive Committee
1995-: Oncology Committee
1996-: Research Committee

St. Francis Hospital:

1985-1995: House Staff Selection Committee
1985-1992: Tissue Committee
1985-1995: Residency Curriculum Committee
1985-1992: Tumor Board Director
1986-1993: Clinical Competence Committee
1987-1989: Audit Committee
1987-1994: Utilization Review Committee
1989-1995: Tumor Committee
1989-1991: Pharmacy and Therapeutics Committee
1991-1995: Chairman, Pharmacy and Therapeutics Committee

Review Board:

1993-1995: Referee, Hospital Formulary

Cooperative Oncology Groups:

1987-1992: Eastern Cooperative Oncology Group-Genito-Urinary Committee
1990-1993: Eastern Cooperative Oncology Group-Head and Neck Committee
1992-1996: Eastern Cooperative Oncology Group-Chairman, Brain Tumor Working Group
1993-1997: Consultant, NABTT CNS Consortium
1996-: Database Co-Chair, Brain Tumor Committee, Eastern Cooperative Oncology Group
1997-: Advisory Board, NABTT CNS Consortium

Memberships in Professional Societies:

1984-: American Society of Hematology
1985-: American Society of Clinical Oncology
1986-1992: Member, American College of Physicians
1986-1990: American Cancer Society, Medical Affairs Committee
1990-1993: Chairman, Medical Affairs Committee, American Cancer Society
1992: Fellow, American College of Physicians
1992-1995: Member, Connecticut Prostate Cancer Study Group
1993-1995: Member, American Cancer Society, Connecticut Division, Medical Affairs Committee
1993-1995: Member, American Cancer Society, Greater Hartford Unit, Board of Directors
1994-: Member, American Association for Cancer Research
1994-: Medicare Carrier Advisory Committee, Hematology Representative (Alternate)
1994-1995: Member, American Cancer Society, Response System Medical Review Team

Teaching Experience:

1985: Teaching Attending, Medical Service, University of Connecticut Health Center
1985-1987: Teaching Attending, Hematology-Oncology Service, Newington VA Hospital
1986-1995: Lectures, Discussion Groups and Laboratory Sessions in Hematology, University of Connecticut Medical School

Community Service:

1987-1989: Cheshire Hospice Board of Directors

Original Reports:

Hellman RM, Rufty AJ. Left ventricular aneurysms caused by blunt chest trauma. Southern Med J 1978; 71:652-655.
Hellman RM, Jackson DV, Buss DH. Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome in HLA-identical siblings. Ann Int Med 1980; 93:283-284.
Ober KP, Hennessy JF, Hellman RM. Severe hypocalcemia associated with chronic glutethimide addiction: A case report. Am J Psychiatry 1981; 1239-1240.
Bradley EC, Issell BF, Hellman RM. The human tumor colony-forming chemotherapy-sensitivity assay: A biological and clinical review. Investigational New Drugs 1984; 2:59-70.
Yoosufani Z, Slavin JD, Hellman RM, Sethi SS, Spencer RP. Pre-leukemia following large dose radioiodide therapy for metastatic thyroid carcinoma. J Nucl Med 1987; 28: 1348-1350.
Hellman RM, Calogero JA, Kaplan BM. VP-16, Vincristine and Procarbazine with Radiation Therapy for treatment of malignant brain tumors. J. Neuro Oncology 1990; 8: 163-166.
Gerardi DA, Hellman RM, Conlon M. Non-Hodgkin’s Lymphoma Presenting with Cardiac Tamponade. Conn Med 1992; 56:11-13.
Dhami M, Bona R, Calogero J, Hellman RM. Venous Thromboembolism and High-Grade Gliomas. Thrombosis and Haemostasis 1993; 70: 393-396.
Price TH, Goodnough LT, Vogler WR, Sacker RA, Hellman RM, Johnston MF, Bolgiano DC, Abels RI. The Effect of Recombinant Human Erythropoietin on the Efficacy of Autologous Blood Donation in Patients with Low Hematocrits: A Multicenter Randomized Double-Blind Controlled Trial. Transfusion 1996; 36: 29-36.
Price TH, Goodnough LT, Vogler WR, Sacker RA, Hellman RM, Johnston MF, Bolgiano DC, Abels RI. Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit; a randomized, double-blind, controlled trial of recombinant human erythropoietin. Am J Med 1996 Aug 26; 101(2A):22S-27S.
Hellman RM, Neuberg D, Wagner H, Grunnet M, Robins HI, Karp D, Flynn P, Adams G. A Therapeutic Trial of Radiation Therapy with Vincristine, Etoposide, and Procarbazine (VVP) in High Grade Intracranial Gliomas: An Eastern Cooperative Oncology Group Study (E2392). Journal of Neuro-Oncology 1998; 37: 55-62.
Shapiro DE, Boggs SR, Rodrigue JR, Urry HL, Algina JJ, Hellman RM, Ewen F. Stage II breast cancer: differences between four coping patterns in side effects during adjuvant chemotherapy. J Psychosom Res 1997 Aug; 43(2):143-57.
Gilbert M, O'Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, Hellman RM. A Phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: An Eastern Cooperative Oncology Group Study (E2393). J Neuro-Oncology 2000 Apr; 47(2):145-52.
Grunnet ML, O'Neill A, Gilbert M, Hellman RH. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with ECOG protocol of pre-irradiation chemotherapy. Clin Neuropathol 2000 Sep-Oct; 19(5):230-4.
Shaw E, Arusell R, Scheithauer B, O'Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman RM, Curran W, Abrams R. Prospective randomized trial of low-dose versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002 May 1; 20(9):2267-76.

Chapters:

Hellman, Richard M. Cancers of the Central Nervous Systems in Current Practice of Medicine, Roger Bone ed. Current Medicine Publishers, Philadelphia, PA, 1995

Abstracts:

Hellman RM, Glass J, Nunes MT. Iron chelators as antineoplastic agents. In: Urushizaki I., Aisen P., Listowsky I., Drysdale J.W. (eds) Structure and Function of Iron Storage and Transport Proteins. Elsevier Science Publishers, New York, 1983, p.479-480.
Hellman RM, Glass J. a,a`dipyridyl as an antineoplastic agent. Blood, suppl., 1983; 62:160a.
Hellman RM, Calogero JA, and Kaplan BM. VP-16, Vincristine and Procarbazine as treatment for recurrent and primary malignant brain tumors. Proc Am Soc Clin Oncol, 1990; 9:361.
Hellman R, Fishman H, Calogero J and Kaplan B. VP-16, Vincristine and Procarbazine with Radiation Therapy for the Treatment of Glioblastoma Multiforme. Proc Am Soc Clin Oncol, 1992; 11:151.
Dhami M. Bona R. Hellman R. High-Grade Gliomas and Venous Thromboembolic Complications. Proc Am Soc Clin Oncol, 1992; 11:154.
Price TH, Goodnough LT, Volger W, Sacher R. Hellman R, Johnston M, Jordan L, Khan N. Abels R, and the EPO Autologous Study Group. The Impact of Recombinant Erythropoietin Administration on the Efficacy of Autologous Blood Strategies in patients with Low Hematocrits. Blood, 1992; 80:219a.
Hellman RM, Fishman H, Calogero J, Kaplan D. Etoposide (VP-16) Vincristine and Procarbazine with Radiation Therapy for the Treatment of Glioblastoma Multiforme. Proc Am Soc Clin Oncol, 1994; 12:181.

Protocols:

New-Haven and Hartford CCOP Protocols:

"Stimulative Androgen Therapy in Combination with Chemotherapy in Hormone Resistant Prostate Cancer." Principle Investigator: Richard M. Hellman, M.D. Activated May, 1986.

Ortho Pharmaceutical Corporation Sponsored Clinical Protocols:

"A double-blind, placebo-controlled study to determine whether r-HEUPO can facilitate presurgical autologous blood donation in patients with low hematocrit levels." Principal Investigator: Richard M. Hellman, M.D.
Phase III treatment protocol for anemia." Principal investigator: Richard M. Hellman, M.D.

Chartwell Foundation and Immunex Corporation Sponsored Clinical Protocols

Treatment of Chemotherapy-Induced Myelosuppression by Administration of GM-CSF: Assessment of the Influence of GM-CSF on the Duration and Maintenance of Hematopoietic Recovery and the Relationship Between Therapy and Patient wlinical Outcome. Activated 9/93.

Amgen Sponsored Clinical Protocols:

"A Phase IV, Open Label, Multicenter study of Neupogen as an Adjuvant to Myelosuppressive Chemotherapy in Cancer Patients." Protocol #GCSF-0914. Principal Investigator: Richard M. Hellman, M.D.

Schering-Plough Research Institute Sponsored Clinical Protocols

"C-94-091-09: A Randomized, Open-Label, Phase II Study of Temozolomide (SCH S2365) and Reference Agent (Procarbazine) in the Treatment of Patients with Glioblastoma Multiforme at First Relapse.” Principal Investigator: Richard M. Hellman, M.D.

Eastern Cooperative Oncology Group Protocols

"E 2392, A Therapeutic Trial of Radiation Therapy with Vincristine, VP-16 and Procarbazine (VVP) in High Grade, Intracranial Gliomas." Study Chairman: Richard M. Hellman, M.D. Activated March, 1992; Closed November, 1993.
ECOG Study Coordinator, R9492, "Phase III Intergroup Randomized Comparison of Radiation Alone versus Pre-radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas."

Interests

Downhill skiing, running, windsurfing, travel